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Abstract: A three-dimensional quantitative structure-activity relationship (3D-QSAR) 
model of sulfonamide analogs binding a monoclonal antibody (MAbSMR) produced against 
sulfamerazine was carried out by Distance Comparison (DISCOtech), comparative 
molecular field analysis (CoMFA), and comparative molecular similarity indices analysis 
(CoMSIA). The affinities of the MAbSMR, expressed as Log10IC50, for 17 sulfonamide 
analogs were determined by competitive fluorescence polarization immunoassay (FPIA). 
The results demonstrated that the proposed pharmacophore model containing two 
hydrogen-bond acceptors, two hydrogen-bond donors and two hydrophobic centers 
characterized the structural features of the sulfonamides necessary for MAbSMR binding. 
Removal of two outliers from the initial set of 17 sulfonamide analogs improved the 
predictability of the models. The 3D-QSAR models of 15 sulfonamides based on CoMFA 
and CoMSIA resulted in q
2
cv values of 0.600 and 0.523, and r
2 values of 0.995 and 0.994, 
respectively, which indicates that both methods have significant predictive capability. 
Connolly surface analysis, which mainly focused on steric force fields, was performed to 
complement the results from CoMFA and CoMSIA. This novel study combining FPIA 
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with pharmacophore modeling demonstrates that multidisciplinary research is useful for 
investigating antigen-antibody interactions and also may provide information required for 
the design of new haptens. 
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1. Introduction 
Sulfonamides are widely used to control a number of diseases in the animal industry and 
aquaculture, as well as for animal growth-promotion [1]. Despite the overall positive effects provided 
by sulfonamides, if inappropriate levels are used to treat livestock, fish and shrimp diseases, 
undesirable residues can remain in tissues, biofluids, and environmental water samples [2,3]. The 
presence of sulfonamide residues in foods of animal origin constitutes a potential health hazard for 
humans due to the increasing incidence of microbial resistance and the risk of allergic reactions to 
sulfonamide residues or to their metabolites.  
Sulfonamides are most often detected using high-performance liquid chromatography with UV, 
fluorescence, or mass spectrometry detection in animal tissues, biofluids, eggs, milk, and in 
environmental water samples [4,5]. The availability of reproducible, sensitive and rapid methods for 
screening sulfonamides in foodstuffs is essential. The antibody-based analytical methods, primarily 
immunoassays, have proven to be useful as simple, fast and sensitive tools for detecting and 
quantifying sulfonamides in a variety of matrices [6]. 
Binding properties of a desirable antibody must meet one of two criteria to be useful in an 
immunoassay: an antibody must either have narrow-specificity or recognize only one analyte with 
high-affinity or, it must have broad-specificity and bind as many analytes as possible with similar 
affinity within a group of structural analogs. Several strategies in hapten design have been used while 
producing monoclonal antibodies (MAbs) and polyclonal antibodies against sulfonamides [7–10]. 
However, the affinity and specificity of the generated antibodies often have non-uniform properties. 
The conventional process for antibody production, when carried out without careful theoretical 
considerations, primarily focuses only on new hapten design and extensive screening protocols, and 
this approach is limited. There is considerable interest in understanding the structural basis of complex 
analyte-antibody interactions. A method that can provide useful information about the topological 
properties of a hapten can be very useful in helping produce an antibody with the desired affinity and 
specificity. Efforts have been made to correlate the affinity of antibodies to conformational and 
electronic properties of a hapten, as previously demonstrated with sulfonamides by using molecular 
modeling methods [8,11]. Also, reports of using a quantitative structure-activity relationship (QSAR) 
model for drugs and drug receptors allowed investigators to predict activity based on the structure of 
the involved molecules [12,13]. A three-dimensional quantitative structure-activity relationship   
(3D-QSAR) model is developed using comparative molecular field analysis (CoMFA) or comparative 
molecular similarity indices analysis (CoMSIA). The CoMFA method uses steric and electrostatic 
fields, whereas the CoMSIA method can use up to five physicochemical properties (steric, electrostatic, 
hydrophobic, and hydrogen-bond (HB) donor and HB acceptor) [14–16]. Several papers have Int. J. Mol. Sci. 2012, 13 6336 
 
 
described the use of 3D-QSAR to study binding interactions of cocaine and digoxin to MAbs by 
CoMFA and CoMSIA methods [17,18]. Results of the studies can be used for future redesign or 
selection of more suitable antibodies.  
In this paper, the affinities (IC50 values) of a murine MAb, raised against sulfamerazine, referred to 
as MAbSMR, were determined for a set of 17 sulfonamides by fluorescence polarization immunoassay 
(FPIA). Structural features of the sulfonamides that demonstrated important interactions with the 
developed MAbSMR were defined using the pharmacophore-searching program Distance Comparison 
(DISCOtech). An enhanced, faster version of DISCO, DISCOtech identifies features of molecular 
interactions that could potentially be elements of a pharmacophore model. The 3D-QSAR analysis 
techniques, CoMFA and CoMSIA, were used to describe the quantitative binding affinities of the 
sulfonamides with the MAbSMR. Finally, the Connolly surface of sulfamerazine (hapten), which exhibited 
the lowest binding affinity to the MAbSMR, was compared with the structures of two sulfonamide 
analogs. This work may develop knowledge of interactions that govern sulfonamide-antibody binding, 
and may help in the design of novel, performance enhanced antibodies. 
2. Results and Discussion 
2.1. Determination of IC50 Values Using FPIA 
FPIA is based on the degree of movement of the observed emission intensity from the vertical to the 
horizontal plane, which is related to the mobility of the fluorescently labeled molecule. There is an 
increase in polarization of the fluorescence when a small fluorescent-labeled antigen (tracer) is bound 
by an antibody, and the method does not use multiple steps or separations, providing simplicity of use 
and higher-speed. Competitive FPIAs employing specific antibodies and fluorescein-labeled antigens 
for determination of drug residues in food samples have been previously studied [19,20].  
Figure 1. (a) Pharmacophore of sulfamerazine and (b) backbone of sulfonamides. 
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The MAbSMR affinity for all sulfonamide analogs was expressed as IC50 values [21]. The structures, 
IC50 and Log10IC50 values of all sulfonamides are summarized in Table 1. The major difference among 
sulfonamide analogs lies in the diverse-array of R-groups linked to the nitrogen at position 7   
(Figure 1a, Table 1). Simple inspection of the IC50 values reveals that the R-group is of primary 
importance for MAbSMR binding of the sulfonamide analogs (Table 1). Significant differences in 
specificity; i.e., IC50 values, were observed for MAbSMR binding to sulfamerazine and the other 16 
sulfonamide analogs. Since the MAbSMR was produced to the sulfamerazine hapten, the sulfonamides 
with close structural similarity, such as sulfamethazine, demonstrated lower IC50 values than that of 
other analogs, which had a more diverse R-group structure from that of sulfamerazine. Even addition 
of a methyl group at position 3 on the pyrimidine ring, as seen in sulfamethazine, reduced the affinity Int. J. Mol. Sci. 2012, 13 6337 
 
 
compared to sulfamerazine by about 3.5-fold (Figure 1a, Table 1). A methyl group at position 5 on the 
pyrimidine ring resulted in favorable MAbSMR binding as was illustrated by the IC50 value (137 ng/mL) 
of sulfadiazine, which does not have a methyl group at position 5 and has a reduced affinity by   
7.2-fold compared to the hapten, sulfamerazine. The size influence of the groups at positions 3 and  
5 on binding affinity can be observed by comparing the IC50 value of sulfamethazine to that of 
sulfadimethoxine (Table 1). It is interesting that the methoxy substituted analog, sulfameter, binds the 
MAbSMR with a 40-fold lower affinity than does sulfamerazine. However, the effect of the methoxy 
oxygen atom at position 4 of the pyrimidine ring on MAbSMR binding is unknown. However, the 
importance of the pyrimidine ring can be shown based on the affinity of the MAbSMR for sulfamerazine  
(IC50 = 19 ng/mL), which is two to four orders of magnitude better than the affinity for other 
sulfonamide analogs where the pyrimidine ring was substituted with a different heterocyclic ring. The 
MAbSMR has a higher-binding affinity for sulfamerazine, sulfamethazine and sulfadiazine, all of which 
contain a pyrimidine ring at position 7. The binding affinity of all sulfonamides spans a broad-range 
that exceeds four orders of magnitude and yet, except for only sulfaphenazole and sulfanilamide, most 
sulfonamides tested were able to significantly inhibit tracer binding to the MAbSMR. 
Table 1. Experimental and Predicted Sulfonamides Binding Affinity to MAbSMR. 
Drugs 
a R  IC50 
Log10IC50 
(exp.) 
CoMFA CoMSIA 
Log10IC50 
(pre.) 
Residual
Log10IC50 
(pre.) 
Residual
SMR  19 1.28 1.24  0.04 1.22  0.06 
SMZ  65.7 1.82  1.87 −0.05 1.93 −0.11 
SDZ  137 2.14  2.10 0.04  2.17  −0.03 
SDM  528 2.72  2.77  −0.05 2.75 −0.03 
SME 
 
760 2.88  2.87 0.01  2.88  0.00 
STZ 
 
1000 3.00  3.03 −0.03 3.00  0.00 
SMP 
 
1056 3.02  3.01  0.01  3.02  0.00 
SMO  1118 3.05  3.01 0.04  2.89  0.16 
SPY 
 
1189 3.07  3.10 −0.03 3.11 −0.04 Int. J. Mol. Sci. 2012, 13 6338 
 
 
Table 1. Cont. 
Drugs 
a  R  IC50 
Log10IC50 
(exp.) 
CoMFA  CoMSIA 
Log10IC50 
(pre.) 
Residual
Log10IC50 
(pre.) 
Residual
SQX  1538 3.20 3.20  0.00 3.17  0.03 
SCP 
N N
Cl 3800 3.58 3.55  0.03 3.60 −0.02 
SMT  6333 3.80 3.83  −0.03 3.82 −0.02 
SMX  9048 3.96 3.94  0.02 3.88  0.08 
SMM  12,667 4.10  4.09  0.01  4.10  0.00 
SFX  19,000 4.28  4.27  0.01  4.33  −0.05 
SPA  >190,000 -  -  -  -  - 
SAM H  >190,000  - -  - - - 
a The sulfonamide abbreviations are as follows: Sulfamerazine (SMR), sulfamethazine (SMZ), 
sulfadiazine (SDZ), sulfadimethoxine (SDM), sulfameter (SME), sulfathiazole (STZ), 
sulfamethoxypyridazine (SMP), sulfamoxole (SMO), sulfapyridine (SPY), sulfaquinoxaline (SQX), 
sulfachloropyridazine (SCP), sulfamethizole (SMT), sulfamethoxazole (SMX), 
sulfamonomethoxine (SMM), sulfisoxazole (SFX), sulfaphenazole (SPA), and sulfanilamide (SAM). 
It is well known that antigen-antibody binding is mainly dependent on molecular shape, defined by 
the geometry and low-energy interactions [22]. Inspection of the two-dimensional structures of the 
sulfonamide analogs could not explain the observed IC50 values or which forces have mainly 
contributed to the observed MAbSMR binding to these sulfonamide analogs. In an effort to determine 
which structural and electronic effects were primarily important for MAbSMR-sulfonamide binding, 
studies using advanced molecular modeling techniques were undertaken. The contribution of the   
R-group structure to the MAbSMR-sulfonamide complex formation was analyzed by building 
pharmacophore and 3D-QSAR models using CoMFA and CoMSIA methods. Although 3D-QSAR 
models were initially used to direct the design of new drugs, they can also  (i) elucidate the 
stereochemical features important for antigen binding and provide insights into the antibody binding 
cavity; (ii) quantitatively predict the binding affinity of antigens and antibodies; and (iii) help guide the 
design of a new and desirable hapten. Int. J. Mol. Sci. 2012, 13 6339 
 
 
2.2. Pharmacophore and Alignment of the Sulfonamides 
The pharmacophore models of all sulfonamide analogs were constructed in Sybyl 7.0 software 
using the DISCOtech program to perform pharmacophore elucidation from pre-computed 
conformations of sulfonamides that bind the MAbSMR. The program identifies features that can be used 
as elements in a pharmacophore model. The pharmacophore model defines the hydrophobic center, HB 
donor center and HB acceptor center. Several pharmacophore models have proven useful for 
identifying molecules that bind receptors and in interpreting interaction mechanisms [13,14]. The 
antigen-antibody complexes form as a result of several intermolecular forces; the five main forces are: 
(a) hydrogen-bonding; (b) coulombic, i.e., electrostatic and dipole-dipole forces; (c) van der Waals;  
(d) hydrophobic interactions; and (e) π–π complementary ring-bonding [23]. Since adhesion forces 
between a small molecule and a protein are mainly non-covalent, the forces governing antigen-antibody 
binding are similar to that of drug-receptor binding. Finding pharmacophores for antibody recognition 
of antigen epitopes can be likened to finding pharmacophores for drug-receptor binding. Defining 
antigen epitopes and understanding antibody-binding mechanisms may lead to the development of 
more desirable antibodies. 
Figure 2. A stereoscopic view of the sulfonamide pharmacophore model derived from 
DISCOtech. (a) A stick frame representation of six sulfonamides is shown in their 
overlapping conformations; and (b) six pharmacophore feature points are shown, i.e., two 
hydrophobic center sites (Hy1 and Hy2), two hydrogen-bond acceptor atom sites (AA1 and 
AA2), and two hydrogen-bond donor atom sites (DA1 and DA2). 
(a) (b) 
The DISCOtech calculation resulted in a total of 76 models, of which 11 included six sulfonamide 
analogs having the highest-affinity to the MAbSMR. The best pharmacophore model was Model 004 
shown in Figure 2a having the highest score of 5.11 and greatest inter-point distance (Dmean) value of 
4.60. The stick drawing shown in Figure 2b represents six sulfonamide analogs in their overlapping 
conformations, which includes sulfamerazine, sulfamethazine, sulfadiazine, sulfadimethoxine, 
sulfameter, and sulfathiazole. This pharmacophore model consists of six pharmacophore feature points; 
i.e., two hydrophobic center sites, one on the benzene (Hy1) and the other on the heterocyclic ring 
(Hy2); two HB acceptor atom sites, one near the oxygen atom on the sulfonyl group at position 10 
(AA1) and the other near the nitrogen at position 6 on the heterocyclic ring (AA2); and two HB donor 
atom sites, one on the NH2 group at position 17 on the benzene ring (DA1) and the other on the Int. J. Mol. Sci. 2012, 13 6340 
 
 
hydrogen-atom in the sulfonyl amine at position 7 (DA2) (Figures 1,2b). Figure 3 shows the 
arrangement of these features in respect to sulfamerazine. The model presented here covers all possible 
epitopes of the sulfonamides that bind the MAbSMR. 
Figure 3. Schematic pharmacophore of the sulfonamides. Pharmacophore feature points 
include two hydrophobic center sites (benzene ring and pyrimidine ring), two hydrogen-bond 
(HB) acceptor atom sites at positions 10 and 6, and two HB donor atom sites at positions 7 
and 17. They are annotated as followed: AA, HB acceptor atom; DA, HB donor atom; and 
Hy, hydrophobic center. The distances between these sites are shown beside each straight 
line in ångström units. 
 
Alignment is a very important step in CoMFA studies, and some papers have shown that the 
resulting 3D-QSAR model is often sensitive to a particular alignment scheme [12,24]. Besides 
identifying the elemental characteristics required for sulfonamide binding to the MAbSMR, the 
DISCOtech derived Model 004 also provided the alignment rule for the CoMFA and CoMSIA studies. 
2.3. CoMFA Analysis 
The general limitation of the pharmacophore model is that it does not include steric and electrostatic 
functionalities responsible for short and long range antigen-antibody interactions [25]. The application 
of CoMFA in QSAR has overcome this limitation and is intuitively helpful in understanding QSAR. 
Therefore, for a more detailed and rigorous analysis of sulfonamide-MAbSMR interactions, the CoMFA 
model was used to correlate the variability in the MAbSMR binding affinities to variations in 
sulfonamide analog molecular structure. 
Four statistically significant and chemically meaningful CoMFA models were developed based on 
superimposition of sulfonamide analogs. Table 2 summarizes the results of these CoMFA studies. The 
CoMFA Model M1 included all 17 sulfonamide analogs, and was a poor predictive model resulting in 
values for leave-one-out (LOO) q
2 of 0.258 and cross-validated q
2
cv of 0.241. When omitting either 
sulfanilamide or sulfaphenazole, the Models M2 or M3 were obtained, respectively, and they had a 
better q
2
cv than that of Model M1, but the q
2
cv remained below 0.5. This may be explained because the 
sulfanilamide and sulfaphenazole substituent groups at position 7 are significantly different from that 
of sulfamerazine, the hapten used for immunization. The R-group of sulfaphenazole may add extra 
steric hindrance restricting binding with the MAbSMR; whereas, the R-group of sulfanilamide ‘H’ most 
likely lacks an adequate epitope to bind with the antibody. An improved CoMFA Model M4 was 
obtained using 15 sulfonamide analogs, without both sulfanilamide and sulfaphenazole. Model M4 Int. J. Mol. Sci. 2012, 13 6341 
 
 
exhibited a satisfactory predictive ability with a cross-validated q
2
cv value of 0.600, non-cross-validated 
r
2 value of 0.995 and standard error of the estimate of 0.071. The contributions of the steric and 
electrostatic fields to binding affinity were 55.8% and 44.2%, respectively, by PLS analysis, indicating 
a strong relationship between the sulfonamide analogs’ structures and binding affinities. In the case of 
sulfonamide-MAbSMR complexes, steric interactions dominated the contribution toward the observed 
binding affinities. Figure 4 shows the correlation between the experimental binding affinities and the 
predicted ones using the CoMFA model. There was good agreement between the experimental and 
predicted values. Table 1 lists experimental binding affinities, predicted binding affinities and residual 
values (defined as the difference between experimental and predicted binding affinity) by CoMFA. The 
resultant residual parameters by CoMFA gave little variation between experimental and predicted 
binding affinities, which implied that the models were robust and would be a useful predictive tool. 
Table 2. Summary of Results of CoMFA Analysis. 
Models 
Delete 
compounds 
  No validation 
Leave-one-out
(LOO) q
2 
Cross-validated
q
2
cv 
Standard error of 
the estimate (SEE)  r
2  F value 
M1 -  0.258  0.241  -  -  - 
M2 SAM  0.126  0.127  -  - - 
M3 SPA  0.310  0.234  -  - - 
M4 SAM,  SPA  0.582  0.600  0.071  0.995  397.263 
q
2, LOO correlation coefficient; q
2
cv, cross-validated correlation coefficient; r
2, non-cross-validated 
correlation coefficient; F value, F-statistic for the analysis. 
Figure 4. Plot of experimental versus predicted affinity values derived from the CoMFA 
and CoMSIA models. 
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Figure 5 features steric and electrostatic contour plots, respectively, from CoMFA analysis that 
show where the changes in steric and electrostatic fields are associated with MAbSMR binding to the 
sulfonamide analogs. Greater values were correlated with more bulk near the green contours and with 
less bulk near the yellow contours (Figure 5a); whereas a more positive charge was correlated with the Int. J. Mol. Sci. 2012, 13 6342 
 
 
blue contours, and a more negative charge with the red contours (Figure 5b). Some of the most 
noticeable features in Figure 5a are the presence of large green areas that indicate improved binding 
affinity with increased steric tolerance in the regions near the NH2 group at position 17 and the NH 
group at position 7 of sulfamerazine (Figure 1). However, even more attention was focused on the  
R-group, since all sulfonamide analogs had differences in the R-group. The green steric contours from 
CoMFA analysis shown in Figure 5a localized near positions 3 and 4 of the pyrimidine ring indicate 
that bulky substituents in this region of the R-group will enhance binding affinity. However, the 
introduction of the methoxyl group in the pyrimidine ring at position 4 decreased the binding affinity 
as seen with sulfameter. This may be due to the effects of other fields like electrostatic, hydrophobic or 
hydrogen-bonding that may play an important role in the interactions of the sulfonamide analogs and 
the MAbSMR. In Figure 5a, the yellow-colored and green-colored regions near position 5 (the 
pyrimidine ring methyl), in respect to the proportion of the two colors, show that small R-groups at 
position 5 increase the binding affinity. 
Figure 5. CoMFA contour plots of (a) steric field and (b) electrostatic field contributions 
of sulfonamides binding the MAbSMR. 
(a) steric field  (b) electrostatic field 
The electrostatic field of the CoMFA model is shown in Figure 5b with the structure of 
sulfamerazine as a reference. The large blue area above the molecule from about position 13 to 
position 18 represents a favorable positive Gasteiger-Hückel charge (Figure 1a). Red-colored regions 
near positions 3 and 5 show that suitable electronegative groups in these regions are favored to bind 
the MAbSMR. This interpretation is born out by the greater binding affinity of sulfadimethoxine,   
having methoxy groups at positions 3 and 5, compared with sulfameter, sulfamethoxypyridazine, or 
sulfachloropyridazine, which are substituted with an electronegative atom at position 4. 
However, even though good q
2
cv and r
2 values were obtained for the CoMFA steric and electrostatic 
correlations with the observed MAbSMR binding affinities, it was difficult to explain all structural 
interactions. Therefore, the more accurate 3D-QSAR technique, CoMSIA, was subsequently used to 
evaluate the data. Int. J. Mol. Sci. 2012, 13 6343 
 
 
2.4. CoMSIA Analysis 
CoMSIA is a relatively new method that adds hydrophobic, and HB donor and HB acceptor fields 
to the established steric and electrostatic CoMFA fields. The five fields are partitioned into spatial 
locations where they play a major role in determining binding affinity. Moreover, a Gaussian function 
is used in CoMSIA to determine the distance dependence, and the similarity indices can also be 
calculated at grid points inside the molecule, not just on the surface, as is the case with CoMFA. 
In this study, several models were produced by using either single or multiple field combinations. 
The models developed using steric and electrostatic fields received a cross-validated correlation 
coefficient q
2
cv of 0.678 (Table 3). When the hydrophobic or HB donor and HB acceptor fields were 
included, the q
2
cv was not improved but actually decreased compared to that of the model where only 
steric and electrostatic fields were considered. When all five fields were included, the q
2
cv decreased to 
0.287. It was observed that inclusion of the hydrophobic field and HB fields did not improve the 
quality of the model, but produced statistically worse results. We then considered the four field model 
(steric, electrostatic and HB donor and HB acceptor) as the best compromise, since the q
2
cv value of 
0.523 and r
2 value of 0.994 was acceptable, and since this model utilized a greater number of possible 
interactions. In the pharmacophore model, two hydrophobic centers, the benzene ring and R-group, 
were expected to exert an important role during formation of the antigen-antibody complex; 
surprisingly, the CoMSIA study revealed that the hydrophobic factor had only a negligible contribution 
to the sulfonamide analogs binding with the MAbSMR. The reason may be based on the extent of the 
hydrophobic interactions of the sulfonamide analogs. We speculate that the hydrophobic force may 
have had an effect on the interactions between the sulfonamide analogs and the MAbSMR, but that force 
may have been negligible during the process of competition compared to other forces such as steric, 
electrostatic, and HB donor and HB acceptor fields. The quality of the final CoMSIA model was 
assessed by inspection of the plots of predicted versus experimental values of Log10IC50. The CoMSIA 
calculated contributions of the molecular field were 10.8% steric, 39.5% electrostatic, 27.8% HB donor, 
and 21.9% HB acceptor. 
Table 3. Summary of Results of CoMSIA Analysis. 
Models 
Steric and 
electrostatic 
Hydrophobic 
Donor 
and 
acceptor
Leave-
one-out 
(LOO) q
2
Cross-
validated 
q
2
cv 
SEE  r
2  F value
              
N1  √ -  -  0.558  0.678  -  -  - 
N2 -  √ -  −0.491  −0.593 -  -  - 
N3 -  -  √ 0.407  0.431  -  -  - 
N4  √  √  √ 0.258  0.287  -  -  - 
N5  √ -  √ 0.450  0.523  0.078  0.994  324.629
N6  √  √ -  0.145  0.133  -  -  - 
N7 -  √  √ 0.084  0.021  -  -  - 
q
2, LOO correlation coefficient; q
2
cv, cross-validated correlation coefficient; SEE, standard error of 
the estimate; r
2, non-cross-validated correlation coefficient; F value, F-statistic for the analysis. Int. J. Mol. Sci. 2012, 13 6344 
 
 
The CoMSIA contour maps are shown in Figure 6. For comparison, the molecule sulfamerazine 
shown in both figures had the best binding affinity. Figure 6a shows the CoMSIA contour map of the 
steric and electrostatic field contributions to the model. Red and blue polyhedra show regions where 
negatively charged and positively charged groups, respectively, will increase binding affinity. The 
green and yellow area located near the R-group at position 3 suggests a strict size requirement at this 
position. The green areas of Figure 7 represent a preferred occupancy of the MAbSMR binding pocket. 
A variation in volume of the substituent at position 3 has a large influence on the degree of MAbSMR 
binding with the sulfonamide analogs. Therefore, groups with increased steric bulk in these regions 
will enhance binding affinity. However, the yellow polyhedra indicate areas where steric bulk is 
unfavorable for binding. The CoMSIA contour plot (Figure 6a) appears more localized and detailed 
compared to the CoMFA plots (Figure 5). Based on the CoMSIA steric and electrostatic field contour 
map, one can speculate that spatial hindrance blocking the binding of larger steric groups is derived 
from amino acid residues in the MAbSMR binding pocket in the area indicated by the yellow polyhedra 
(Figure 6a). Additionally, the importance of electrostatic interactions is shown with a red contour 
localized near position 3, suggesting that analogs having a heterocyclic ring with an electron-rich atom 
near position 3 enhance the binding affinity. 
Figure 6. The contour plots of CoMSIA steric, electrostatic, hydrogen-bond (HB) donor 
and HB acceptor fields.  
(a) steric, electrostatic fields  (b) hydrogen-bond (HB) donor and HB acceptor fields 
Figure 6b shows the contribution of the HB donor and HB acceptor regions of the best model 
derived by CoMSIA. The CoMSIA HB donor contour map shown with cyan contours near the nitrogen 
atom at position 17 and the oxygen atom at position 8 will be favorable for binding affinity, while the 
purple isopleths near the sulfonamido group at positions 7, 8, 9 and 10 suggest that a HB acceptor  
R-group is unfavorable for binding affinity. Magenta isopleths are mainly concentrated on the 
heterocyclic ring where a HB acceptor group in the sulfonamide analogs would enhance binding 
affinity. This is in agreement with the CoMSIA electrostatic field model, showing that an electron-rich 
atom acts as a HB acceptor, which explains why the compounds with a nitrogen, oxygen or sulfur atom 
at position 3 in the heterocyclic ring exhibit better binding than those without an electron-rich atom at 
this position. Int. J. Mol. Sci. 2012, 13 6345 
 
 
2.5. Connolly Surface Analysis of Sulfonamides 
As previously discussed in the FPIA, and CoMFA and CoMSIA sections, the MAbSMR binding 
affinity is sensitive to an R-group with steric bulk at position 7 of the sulfonamide. In the process of 
deriving the CoMFA and CoMSIA models, two sulfonamide analogs, sulfaphenazole and sulfanilamide, 
were excluded from the data set. The QSAR derived from the CoMSIA model indicated that the steric 
factor plays an important role in the MAbSMR binding affinity for sulfonamide analogs. Therefore, 
substituent size and shape clearly are important for sulfonamide binding, and this is in agreement with 
the generally accepted concept that shape complementarity governs antigen binding to antibodies [16,17]. 
In this study, the importance of shape complementarity is reflected in the low affinities displayed by 
sulfaphenazole and sulfanilamide. The requirement for the appropriate size steric bulk of the R-group 
for high-binding affinity can be seen by observing the IC50 values (Table 1). All sulfonamide analogs 
show a lower-affinity to the MAbSMR than does sulfamerazine. For clarity purposes, the structures of 
two sulfonamide analogs, sulfaphenazole and sulfanilamide, were correlated with the Connolly surface 
of sulfamerazine. The Connolly surface is the van der Waals surface of a molecule that is accessible to 
solvent molecules, in this case water. A Connolly surface is generated by rolling a probe sphere over 
the van der Waals surface of the molecule of interest [26].  
The green dotted area in Figure 7a represents the Connolly surface of sulfamerazine, and the 
structures of sulfanilamide (Figure 7b) and sulfaphenazole (Figure 7c) were superimposed onto the 
Connolly surface of sulfamerazine. Changes in the sulfonamide R-group produced significant changes 
in the shape of the sulfonamides tested. Figure 7b shows that reducing the R-group at position 7 in the 
sulfanilamides resulted in changing the molecular shape compared to that of sulfamerazine. More 
importantly, the loss of one hydrophobic center (Hy) and one HB acceptor atom (AA) in sulfanilamide 
may be responsible for important MAbSMR binding interactions. However, increased R-group volume 
also decreased the binding affinity of sulfonamide analogs to the MAbSMR, as shown by sulfaphenazole 
whose phenazole group protrudes from the Connolly surface of sulfamerzine (Figure 7c), again 
suggesting that a strict fit between the MAbSMR’s binding pocket and the sulfonamide R-group is 
important. The protruding bulky phenazole group is likely restricted by residues from the MAbSMR. It 
may be concluded that the methyl-pyrimidine of sulfamerazine may be deeply buried in the MAbSMR’s 
binding pocket, while other sulfonamide analog R-groups may not be able to enter the binding pocket 
as well or the R-group may be too small, resulting in weaker binding interactions. 
Figure 7. Connolly surface of (a) sulfamerazine expressed by the green dotted area. The 
optimized conformations of (b) sulfanilamide; and (c) sulfaphenazole were superimposed 
onto the sulfamerazine Connolly surface. 
(a) (b) (c) Int. J. Mol. Sci. 2012, 13 6346 
 
 
3. Experimental Section  
3.1. Tracer and Monoclonal Antibody 
The tracer used in the binding affinity determinations, fluorescein isothiocyanate (FITC) labelled 
sulfamethazine (SMZ-FITC), was synthesized and purified using thin-layer chromatography (TLC) in 
a similar way to the method used to make sulfamerazine-FITC [21]. The MAbSMR was previously 
raised from mice immunized with sulfamerazine bound to bovine serum albumin using glutaraldehyde 
as the coupling reagent [21]. 
3.2. Sulfonamides 
Sulfamerazine, sulfamethazine, sulfadiazine, sulfadimethoxine sulfameter, sulfathiazole, 
sulfamethoxypyridazine, sulfamoxole, sulfapyridine, sulfaquinoxaline, sulfachloropyridazine, 
sulfamethizole, sulfamethoxazole, sulfamonomethoxine, sulfisoxazole, sulfaphenazole and 
sulfanilamide were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
3.3. Fluorescence Polarization Immunoassay 
The binding affinity (IC50, 50% inhibition of control activity) values of the MAbSMR with 17 
sulfonamides were determined by a previously developed FPIA method [21]. 
The ability of the sulfonamides to compete with the tracer SMZ-FITC for binding with the MAbSMR 
was studied by measuring inhibition curves. The inhibition curves were constructed using a 
sulfonamide stock solution diluted with borate buffer (50 mM, pH 8.0, 0.1% sodium azide) to give 
0.01, 0.1, 1, 10, 100, 1000, 10,000, 100,000 ng/mL. The SMZ-FITC tracer solution (approximately  
10× background signal of borate buffer) was prepared by dissolving SMZ-FITC with borate buffer. 
The assay was conducted as follows: Six hundred and fifty microliters of a sulfonamide standard 
solution, 650 μL of the tracer solution and 650 μL of the MAbSMR at the optimal dilution (1/34,500) 
were sequentially added to 3 mL cuvettes, mixed, and following a 5 min incubation at room 
temperature, the fluorescence polarization was measured. The IC50 values were converted to Log10IC50.  
3.4. Energy Minimization 
Minimum energy conformations of all 17 sulfonamide analogs were calculated using the Minimize 
module of Sybyl 7.0. The force field was calculated with MMFF94 at an 8 Å cutoff for non-bonded 
interactions, and the atomic point charges were also calculated with MMFF94. Minimizations were 
achieved using the consecutive steepest descent method for the first 100 steps, conjugate gradient 
(Powell) and quasi-Newton (BFGS; named for its originators, approximates the inverse of the Hessian 
matrix) energy minimization steps until the root-mean-square (RMS) of the gradient became less than 
0.005 kcal/mol Å. 
3.5. Data Set Alignment Using DISCOtech 
The DISCOtech program in Sybyl 7.0 was used to align the pharmacophores because it could 
superimpose conformations reflecting the best binding affinity of the analogs. DISCOtech is based on Int. J. Mol. Sci. 2012, 13 6347 
 
 
the assumption that a given set of molecules related by their pharmacological activities may   
possess consensus features [27]. A stochastic structure conformation search was run to generate a 
maximum of 100 conformers for each molecule on the basis of maximum diversity to cover as   
many probable conformers as possible. Since sulfamerazine was used as the hapten to generate the  
MAbSMR, sulfamerazine was selected as the reference compound. For each conformation, the possible 
pharmacophoric elements were assigned. Five (or fewer) conformations with maximum diversity were 
selected for each molecule and aligned to sulfamerazine. DISCOtech initially assigns pharmacophore 
elements such as HB donor atoms, HB acceptor atoms, charged centers, hydrophobic groups, and the 
most likely location of sulfonamide binding sites with the MAbSMR. The distances between the feature 
points in each sulfonamide conformation were calculated and compared with those of the reference 
compound. The distance tolerance was set stepwise from 0.25 to 2.5 Å by 0.25 Å increments. If all the 
intra-molecular distances of identical features between the reference conformation and the calculated 
conformations of other sulfonamides were met within the tolerance, a valid pharmacophore model was 
established. The final pharmacophore model with the highest score and lowest pairwise tolerance was 
proposed and subjected to CoMFA and CoMSIA calculations. The score was calculated according to 
the following formula [28]: 
(0 . 5 )
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where H is the number of molecules that match the model, M is the number of targets (molecules in the 
input set), k is the number of features, dij is the interfeature distance, and do equals 2 Å. 
3.6. CoMFA Analysis 
For CoMFA calculations [27], the alignment molecules were placed in a 3D-cubic lattice with a 2 Å 
grid in the x, y and z directions. The default sp
3-hybridized carbon atom with a +1 charge was selected 
as the probe atom for the calculation of the steric (Lennard-Jones 6–12 potential) and electrostatic 
fields (Coulombic potential) around the aligned molecules with a distance-dependent dielectric 
constant at all lattice points. Values of steric and electrostatic energy were truncated to 30 kcal/mol 
avoiding infinity energy values inside the molecules. 
3.7. CoMSIA Analysis 
Similarity indices descriptors were derived with the same lattice box that was used in the CoMFA 
calculations. The CoMSIA method defines five fields: steric, electrostatic, hydrophobic, HB donor and 
HB acceptor. A probe atom with a radius of 1.0 Å, +1 charge, hydrophobicity of +1.0, and HB donor 
and HB acceptor properties of +1.0 was used to calculate steric, electrostatic, hydrophobic, and HB 
donor and HB acceptor fields. Gaussian type distance dependence was determined between the grid 
point and each atom of the molecule, and the default value for the attenuation factor (α) was set to  
0.3 [14,15,29]. Int. J. Mol. Sci. 2012, 13 6348 
 
 
3.8. Partial Least Squares (PLS) Regression Analysis 
PLS methodology was used for all 3D-QSAR analyses to determine the significance of the models. 
Column filtering was set to 1.0 kcal/mol to speed up the analysis and reduce noise so that only those 
steric and electrostatic energies with values greater than 1.0 kcal/mol were considered in the PLS 
analysis. The CoMFA and CoMSIA descriptors served as independent variables and the Log10IC50 
values as dependent variables in PLS regression analyses. The predictive value of the models (q
2) was 
evaluated using the leave-one-out (LOO) cross-validation method. The cross-validated coefficient, q
2
cv, 
was calculated using the following equation: 
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where Ypre represents the calculated binding affinity, Yexp is the experimentally determined binding 
affinity, and Ymean is the mean value of the target property (Log10IC50). 
The optimum number of components used to derive the non-cross-validated model was defined as 
the number of components leading to the highest non-cross-validated r
2, standard error of the estimate, 
and F value. At the same time, the CoMFA and CoMSIA color contour maps were derived for the 
steric and electrostatic fields. The quality of the final CoMFA and CoMSIA models was measured by 
two statistical parameters: q
2
cv and r
2. The value of q
2
cv indicates the predictive capacity of the model, 
and should be greater than 0.5; and the value of r
2 shows the self-consistency of the model, and should 
be greater than 0.90 [30]. 
3.9. Connolly Surface 
The Connolly surface was calculated for sulfamerazine using the standard implementation in the 
Sybyl 7.0 package. To calculate the Connolly surface of sulfamerazine, the probe sphere radius was set 
to 1.4 Å, corresponding to the van der Waals radius of water. 
4. Conclusions 
This paper provides a detailed QSAR that includes CoMFA and CoMSIA studies on 17 sulfonamide 
analogs binding the MAbSMR produced against sulfamerazine. The pharmacophore model using 
DISCOtech and the Connolly surface analysis were investigated to show the differences in 
sulfonamide analogs resulting in different observed FPIA derived binding affinities. DISCOtech 
revealed that differences in structural size and shape were the primary reasons for the different 
observed MAbSMR binding affinities. The Connolly surface analysis was a useful tool for comparing 
molecular structures to a predicted binding surface, and may be useful to help discern factors 
governing interactions of small molecules and antibodies. The developed CoMFA and CoMSIA 
models had excellent agreement with 15 of the 17 sulfonamides studied, and will be able to predict 
binding affinities for the MAbSMR with new sulfonamides. Results from this multidisciplinary research 
can also provide insights into key structural elements required to design new haptens for development 
of more desirable antibodies. Int. J. Mol. Sci. 2012, 13 6349 
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